• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

男性乳腺癌患者中HER2表达及通路状态：6150例患者的综合分析结果

HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients.

作者信息

Lyu Boqiang, Zhao Shidi, Wang Hui, Gong Shouping, Wang Biyuan

机构信息

Department of Neurosurgery, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710014, Shaanxi Province, China.

Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, China.

出版信息

Sci Rep. 2025 Jan 27;15(1):3354. doi: 10.1038/s41598-025-86556-0.

DOI:10.1038/s41598-025-86556-0
PMID:39870698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11772752/
Abstract

The role of human epidermal growth factor 2 (HER2) in male breast cancer (MBC) is poorly defined. A comprehensive description of HER2 status was conducted. A total of 6,015 MBC patients from 45 studies and 135 MBC patients with sequencing data were identified. HER2 positive rates and hazard ratios (HR) for overall survival (OS) were combined using Metaprop. The prevalence of HER2 + MBC was 10.0% (95% CI: 8.0-13.0%). Subgroup analyses showed that 7% (95% CI: 2.0-14.0%) had HER2 + protein overexpression. 10% of MBC patients had HER2 + overexpression and/or gene amplification. Asian MBC patients had the highest HER2 + incidence of 17% (95% CI: 12.0-22.0%). The prevalence of HER2 positive MBC fluctuated widely from 2001 to 2015 and then stabilized at 10%. HER2 positivity was significantly correlated with worse OS than negative ones (HR = 1.92, 1.47-2.51). The proportion of HER2 + MBC was inconsistent with the results for the intrinsic HER2-enriched subtype. Altered genes in HER2 + MBC, such as ERBB2, AGO2, RECQL4, and CLTC, were not detected in HER2-MBC. Genomic analysis revealed differences between the patients with HER2 + MBC and those with HER2 + FBC. The percentage of HER2 + MBC was slightly lower than that of women. Multiple approaches may be needed to jointly assess HER2 status in MBC.

摘要

人表皮生长因子2（HER2）在男性乳腺癌（MBC）中的作用尚不明确。本研究对HER2状态进行了全面描述。共纳入了来自45项研究的6015例MBC患者以及135例有测序数据的MBC患者。使用MetaProp软件合并HER2阳性率和总生存期（OS）的风险比（HR）。HER2阳性MBC的患病率为10.0%（95%置信区间：8.0 - 13.0%）。亚组分析显示，7%（95%置信区间：2.0 - 14.0%）的患者存在HER2蛋白过表达。10%的MBC患者存在HER2过表达和/或基因扩增。亚洲MBC患者的HER2阳性发生率最高，为17%（95%置信区间：12.0 - 22.0%）。2001年至2015年期间，HER2阳性MBC的患病率波动较大，随后稳定在10%。HER2阳性患者的OS明显比阴性患者差（HR = 1.92，1.47 - 2.51）。HER2阳性MBC的比例与HER2富集内在亚型的结果不一致。在HER2阴性MBC中未检测到HER2阳性MBC中改变的基因，如ERBB2、AGO2、RECQL4和CLTC。基因组分析揭示了HER2阳性MBC患者与HER2阳性女性乳腺癌（FBC）患者之间的差异。HER2阳性MBC的比例略低于女性。可能需要多种方法联合评估MBC中的HER2状态。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/216d940ad46c/41598_2025_86556_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/082426789d67/41598_2025_86556_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/91ebeccfd790/41598_2025_86556_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/77f3309e0d88/41598_2025_86556_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/b367e2a2ada4/41598_2025_86556_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/e4e46ed2d8c2/41598_2025_86556_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/0cac26d69c85/41598_2025_86556_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/19f3c56710f7/41598_2025_86556_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/54b75dd68aeb/41598_2025_86556_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/216d940ad46c/41598_2025_86556_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/082426789d67/41598_2025_86556_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/91ebeccfd790/41598_2025_86556_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/77f3309e0d88/41598_2025_86556_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/b367e2a2ada4/41598_2025_86556_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/e4e46ed2d8c2/41598_2025_86556_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/0cac26d69c85/41598_2025_86556_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/19f3c56710f7/41598_2025_86556_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/54b75dd68aeb/41598_2025_86556_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ca46/11772752/216d940ad46c/41598_2025_86556_Fig9_HTML.jpg

相似文献

1
HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients.男性乳腺癌患者中HER2表达及通路状态：6150例患者的综合分析结果
Sci Rep. 2025 Jan 27;15(1):3354. doi: 10.1038/s41598-025-86556-0.
2
The Association between ER, PR, HER2, and ER-/PR+ Expression and Lung Cancer Subsequent in Breast Cancer Patients: A Retrospective Cohort Study Based on SEER Database.基于 SEER 数据库的回顾性队列研究：乳腺癌患者中 ER、PR、HER2 和 ER-/PR+ 表达与肺癌后续发生的相关性。
Breast J. 2023 Nov 11;2023:7028189. doi: 10.1155/2023/7028189. eCollection 2023.
3
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益：一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
4
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
5
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
Patterns of presentation, treatment, and survival among older adults with metastatic breast cancer: Results from a large prospective registry.老年转移性乳腺癌患者的临床表现、治疗及生存模式：一项大型前瞻性登记研究的结果
J Geriatr Oncol. 2025 Jun;16(5):102261. doi: 10.1016/j.jgo.2025.102261. Epub 2025 May 19.
7
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.来曲唑联合拉帕替尼和曲妥珠单抗一线治疗人表皮生长因子受体 2（HER2）过表达的转移性激素受体阳性乳腺癌的系统评价和经济分析。
Health Technol Assess. 2011;15(42):1-93, iii-iv. doi: 10.3310/hta15420.
8
Platinum-containing regimens for metastatic breast cancer.转移性乳腺癌的含铂方案。
Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.
9
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
10
Sertindole for schizophrenia.用于治疗精神分裂症的舍吲哚。
Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2.

本文引用的文献

1
SRplot: A free online platform for data visualization and graphing.SRplot：一个免费的在线数据可视化和绘图平台。
PLoS One. 2023 Nov 9;18(11):e0294236. doi: 10.1371/journal.pone.0294236. eCollection 2023.
2
A comprehensive study on surveillance outcomes of a male population followed at a hereditary breast cancer high-risk consultation at a Portuguese tertiary hospital.葡萄牙一家三级医院遗传性乳腺癌高危咨询门诊随访的男性人群监测结果的综合研究。
J Cancer Res Clin Oncol. 2023 Oct;149(13):11145-11156. doi: 10.1007/s00432-023-04994-7. Epub 2023 Jun 22.
3
Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.
男性乳腺癌风险与 BRCA1/2 以外基因的致病性变异相关：一项义大利病例对照研究。
Eur J Cancer. 2023 Jul;188:183-191. doi: 10.1016/j.ejca.2023.04.022. Epub 2023 May 2.
4
Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.定义具有预后能力的男性乳腺癌基因组、转录组、蛋白质组、表观遗传和表型生物标志物：一项系统综述。
Lancet Oncol. 2023 Feb;24(2):e74-e85. doi: 10.1016/S1470-2045(22)00633-7.
5
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09).男性乳腺癌亚型对临床特征和结局的影响：韩国多中心研究（KCSG BR16-09）。
Cancer Res Treat. 2023 Jan;55(1):123-135. doi: 10.4143/crt.2021.1561. Epub 2022 Mar 24.
6
Clinical features and prognostic factors of male breast cancer . female breast cancer.男性乳腺癌与女性乳腺癌的临床特征及预后因素
Transl Cancer Res. 2021 May;10(5):2199-2209. doi: 10.21037/tcr-21-1.
7
Male Breast Cancer: Clinical, Demographical, and Pathological Features in a Cohort of 41 Patients.男性乳腺癌：41例患者队列的临床、人口统计学及病理特征
Cureus. 2021 Sep 8;13(9):e17812. doi: 10.7759/cureus.17812. eCollection 2021 Sep.
8
Transcriptome of Male Breast Cancer Matched with Germline Profiling Reveals Novel Molecular Subtypes with Possible Clinical Relevance.与种系分析相匹配的男性乳腺癌转录组揭示了具有潜在临床相关性的新型分子亚型。
Cancers (Basel). 2021 Sep 8;13(18):4515. doi: 10.3390/cancers13184515.
9
Genetic predisposition to male breast cancer in Poland.波兰男性乳腺癌的遗传易感性。
BMC Cancer. 2021 Aug 30;21(1):975. doi: 10.1186/s12885-021-08718-3.
10
Male breast cancer: an update.男性乳腺癌：最新进展。
Virchows Arch. 2022 Jan;480(1):85-93. doi: 10.1007/s00428-021-03190-7. Epub 2021 Aug 30.